S-HERTOGENBOSCH, Netherlands--(BUSINESS WIRE)--Amphera B.V., a late-stage biotechnology company developing MesoPher cell therapy to treat cancer, today announces that the EMA Committee for Orphan Medicinal Products (COMP) has recommended the granting of orphan medicinal product designation for MesoPher in pancreatic cancer.
Biotechnology company Amphera has reported data from the Phase II Reactive trial and the Phase II/III DENIM trial of MesoPher cell therapy.
Amphera Announces Clinical Updates of MesoPher Cell Therapy
Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of MesoPher cell therapy to treat pleural mesothelioma.